Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Petrillo

Showing results (1-10 of 138) with videos related to

Pageof 14
Sort By:
Expert Opinion on Investigational Drugs|February 21, 2012
Novel targets for VEGF-independent anti-angiogenic drugsMarco Petrillo, Giovanni Scambia, Gabriella Ferrandina
Expert Opinion on Drug Safety|October 6, 2018
The safety of bevazicumab for the treatment of ovarian cancerCarolina Bottoni, Giovanni Scambia, Anna Fagotti, et al.
Expert Opinion on Therapeutic Targets|June 18, 2009
Targeting CD133 antigen in cancerGabriella Ferrandina, Marco Petrillo, Giuseppina Bonanno, et al.
Diagnostic Pathology|October 4, 2011
Vulvar squamous cell carcinoma with sarcoma-like stroma: a case report and review of the literatureMarco Petrillo, Giacomo Corrado, Arnaldo Carbone, et al.
World Journal of Surgical Oncology|August 30, 2008
Conservatively treated glassy cell carcinoma of the cervixGabriella Ferrandina, Vanda Salutari, Marco Petrillo, et al.
BMC Surgery|October 29, 2021
Laparoscopic splenectomy both for primary cytoreductive surgery for advanced ovarian cancer and for secondary surgery for isolated spleen recurrence: feasibility and techniqueAntonio Macciò, Elisabetta Sanna, Fabrizio Lavra, et al.
BMC Cancer|December 17, 2008
Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcomeFrancesco Legge, Marco Petrillo, Vincenzo Adamo, et al.
Gynecologic Oncology|March 18, 2008
Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancerGabriella Ferrandina, Manuela Ludovisi, Giacomo Corrado, et al.
Current Pharmaceutical Design|March 7, 2012
Novel VEGF-independent strategies targeting tumor vasculature: clinical aspectsMarco Petrillo, Maddalena Borriello, Gilda Fuoco, et al.
International Journal of Surgical Pathology|May 16, 2009
Colonic carcinoma metastatic to the endometrium: the importance of clinical history in averting misdiagnosis as a primary endometrial carcinomaGian Franco Zannoni, Valerio Gaetano Vellone, Guido Fadda, et al.
Pageof 14

Showing results (1-10 of 138) with videos related to

Sort By:
Pageof 14
Expert Opinion on Investigational Drugs|February 21, 2012
Novel targets for VEGF-independent anti-angiogenic drugsMarco Petrillo, Giovanni Scambia, Gabriella Ferrandina
Expert Opinion on Drug Safety|October 6, 2018
The safety of bevazicumab for the treatment of ovarian cancerCarolina Bottoni, Giovanni Scambia, Anna Fagotti, et al.
Expert Opinion on Therapeutic Targets|June 18, 2009
Targeting CD133 antigen in cancerGabriella Ferrandina, Marco Petrillo, Giuseppina Bonanno, et al.
Diagnostic Pathology|October 4, 2011
Vulvar squamous cell carcinoma with sarcoma-like stroma: a case report and review of the literatureMarco Petrillo, Giacomo Corrado, Arnaldo Carbone, et al.
World Journal of Surgical Oncology|August 30, 2008
Conservatively treated glassy cell carcinoma of the cervixGabriella Ferrandina, Vanda Salutari, Marco Petrillo, et al.
BMC Surgery|October 29, 2021
Laparoscopic splenectomy both for primary cytoreductive surgery for advanced ovarian cancer and for secondary surgery for isolated spleen recurrence: feasibility and techniqueAntonio Macciò, Elisabetta Sanna, Fabrizio Lavra, et al.
BMC Cancer|December 17, 2008
Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcomeFrancesco Legge, Marco Petrillo, Vincenzo Adamo, et al.
Gynecologic Oncology|March 18, 2008
Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancerGabriella Ferrandina, Manuela Ludovisi, Giacomo Corrado, et al.
Current Pharmaceutical Design|March 7, 2012
Novel VEGF-independent strategies targeting tumor vasculature: clinical aspectsMarco Petrillo, Maddalena Borriello, Gilda Fuoco, et al.
International Journal of Surgical Pathology|May 16, 2009
Colonic carcinoma metastatic to the endometrium: the importance of clinical history in averting misdiagnosis as a primary endometrial carcinomaGian Franco Zannoni, Valerio Gaetano Vellone, Guido Fadda, et al.
Pageof 14